Frauenheilkunde up2date, Inhaltsverzeichnis Frauenheilkunde up2date 2016; 10(06): 487-505DOI: 10.1055/s-0042-117550 Allgemeine Gynäkologie und gynäkologische Onkologie Georg Thieme Verlag KG Stuttgart · New York Myome – Entstehung, Diagnostik und Therapie Johannes Schmid , Jelena Petresin , Andreas Müller , Alexander Boosz Artikel empfehlen Abstract Artikel einzeln kaufen Alle Artikel dieser Rubrik Volltext Referenzen Literatur 1 Robboy SJ, Bentley RC, Butnor K et al. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000; 108: 779-784 2 Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435-438 3 AQUA: Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH. Bundesauswertung zum Verfahrensjahr 2012 15/1, Gynäkologische Operationen; 2013. Im Internet: http://www.sgg.de/downloads/Bundesauswertungen/2012/bu_Gesamt_15N1-GYN-OP_2012.pdf Stand: 11.02.2016 4 Flake PG. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003; 111: 1037-1054 5 Ross RK, Pike MC, Vessey MP et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986; 293: 359-362 6 Chiaffarino F, Parazzini F, La Vecchia C et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999; 106: 857-860 7 Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol 2000; 13: 285-294 8 Walker CL. Role of hormonal and reproductive factors in the etiology and treatment of uterine leiomyoma. Recent Prog Horm Res 2002; 57: 277-294 9 Townsend DE, Sparkes RS, Baluda MC et al. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970; 15: 1168-1173 10 Stewart EA. Uterine fibroids. Lancet 2001; 357: 293-298 11 Friedman AJ, Barbieri RL, Doubilet PM et al. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404-409 12 Brandon DD, Bethea CL, Strawn EY et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993; 169: 78-85 13 Segaloff A, Weed JC, Sternberg WH et al. The progesterone therapy of human uterine leiomyomas. J Clin Endocrinol Metab 1949; 9: 1273-1291 14 Murphy AA, Kettel LM, Morales AJ et al. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76: 513-517 15 Carr BR, Marshburn PB, Weatherall PT et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993; 76: 1217-1223 16 Friedman AJ, Daly M, Juneau-Norcross M et al. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years. Hum Reprod 1994; 9: 1618-1625 17 Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 2000; 108: 791-793 18 Ligon AH, Morton CC. Genetics of uterine leiomyomata. Genes Chromosomes Cancer 2000; 28: 235-245 19 National Collaborating Centre for Womenʼs and Childrenʼs Health. National Institute for Clinical Excellence. Fertility: Assessment and Treatment for People with Fertility Problems. London: RCOG Press; 2004 20 Bhave Chittawar P, Franik S, Pouwer AW et al. Minimally invasive surgical techniques versus open myomectomy for uterine fibroids. Cochrane Database Syst Rev 2014; (10) CD004638 21 Donnez J, Jadoul P. What are the implications of myomas on fertility?. Hum Reprod 2002; 17: 1424-1430 22 Grigorieva V, Chen-Mok M, Tarasova M et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79: 1194-1198 23 Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception 2007; 75: 193-198 24 Zapata LB, Whiteman MK, Tepper NK et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception 2010; 82: 41-55 25 Engman M, Granberg S, Williams AR et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009; 24: 1870-1879 26 Fiscella K, Eisinger SH, Meldrum S et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006; 108: 1381-1387 27 Mavrelos D, Ben-Nagi J, Davies A et al. The value of pre-operative treatment with GnRH analogues in women with submucous fibroids: a double-blind, placebo controlled randomized trial. Hum Reprod 2010; 25: 2264-2269 28 Matchar DB, Myers ER, Barber MW et al. Management of uterine fibroids. Evid Rep Technol Assess (Summary) 2001; 34: 1-6 29 Donnez J, Tomaszewski J, Vázquez F et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421-432 30 Donnez J, Tatarchuk TF, Bouchard P et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409-420 31 Donnez J, Vázquez F, Tomaszewski J et al. PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565-1573 32 Jirecek S, Lee A, Pavo I et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004; 81: 132-136 33 Palomba S, Russo T, Orio F et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 2002; 17: 3213-3219 34 Palomba S, Orio S, Morelli M et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002; 87: 3603-3608 35 Hilário SG, Bozzini N, Borsari R et al. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril 2009; 91: 240-243 36 Parsanezhad ME, Azmoon M, Alborzi S et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010; 93: 192-198 37 ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin: surgical alternatives to hysterectomy in the management of leiomyomas. Int J Gynaecol Obstet 2001; 73: 285-294 38 Parker WH. Uterine myomas: management. Fertil Steril 2007; 88: 255-271 39 Fernandez H, Sefrioui O, Virelizier C et al. Hysteroscopic resection of submucosal myomas in patients with infertility. Hum Reprod 2001; 16: 1489-1492 40 Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91: 1215-1223 41 Dessolle L, Soriano D, Poncelet C et al. Determinants of pregnancy rate and obstetric outcome after laparoscopic myomectomy for infertility. Fertil Steril 2001; 76: 370-374 42 Li TC, Mortimer R, Cooke ID. Myomectomy: a retrospective study to examine reproductive performance before and after surgery. Hum Reprod 1999; 14: 1735-1740 43 Campo S, Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotropin-releasing hormone analogues. Hum Reprod 1999; 14: 44-48 44 Ahmad G, OʼFlynn H, Hindocha A et al. Barrier agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev 2015; (4) CD000475 45 Nieboer TE, Johnson N, Lethaby A et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2009; (3) CD003677 46 Lethaby A, Mukhopadhyay A, Naik R. Total versus subtotal hysterectomy for benign gynaecological conditions. Cochrane Database Syst Rev 2012; (4) CD004993 47 Boosz A, Lermann J, Mehlhorn G et al. Comparison of re-operation rates and complication rates after total laparoscopic hysterectomy (TLH) and laparoscopy-assisted supracervical hysterectomy (LASH). Eur J Obstet Gynecol Reprod Biol 2011; 158: 269-273 48 Mueller A, Boosz A, Koch M et al. The Hohl instrument for optimizing total laparoscopic hysterectomy: results of more than 500 procedures in a university training center. Arch Gynecol Obstet 2012; 285: 123-127 49 Food and Drugs Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Im Internet: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm Stand: 12.12.2016 50 Beckmann MW, Juhasz-Böss I, Denschlag D et al. Surgical methods for the treatment of uterine fibroids – risk of uterine sarcoma and problems of morcellation: Position paper of the DGGG. Geburtsh Frauenheilkd 2015; 75: 148-164 51 Pritts EA, Vanness DJ, Berek JS et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol Surg 2015; 12: 165-177 52 Barakat EE, Bedaiwy MA, Zimberg S et al. Robotic-assisted, laparoscopic, and abdominal myomectomy: a comparison of surgical outcomes. Obstet Gynecol 2011; 117: 256-265 53 Mueller A, Oppelt P, Ackermann S et al. The Hohl Instrument for optimizing total laparoscopic hysterectomy procedures. J Minim Invasive Gynecol 2005; 12: 432-435 54 Thiel F, Renner S, Oppelt P et al. Establishment of total laparoscopic hysterectomy (TLH) in a university gynecology department: results of the first 100 operations. Geburtsh Frauenheilk 2006; 66: 665-669 55 Spies JB, Spector A, Roth AR et al. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002; 100: 873-880 56 Stroszczynski C, Degenhart C. Uterusmyomembolisation und fokussierter Ultraschall: Stand 2013. Gynäkologe 2014; 47: 19-25 57 Tropeano G, Di Stasi C, Amoroso S et al. Long-term effects of uterine fibroid embolization on ovarian reserve: a prospective cohort study. Fertil Steril 2010; 94: 2296-2300 58 Froeling V, Meckelburg K, Schreiter NF et al. Outcome of uterine artery embolization versus MR-guided high-intensity focused ultrasound treatment for uterine fibroids: long-term results. Eur J Radiol 2013; 82: 2265-2269 59 Gupta JK, Sinha A, Lumsden MA et al. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2014; (12) CD005073 60 Müller A, Thiel F, Binder H et al. Myome – Teil 1. Geburtsh Frauenheilk 2004; 64: R230-R243 61 Müller A, Thiel F, Binder H et al. Myome – Teil 2. Geburtsh Frauenheilk 2004; 64: R245-R260 62 Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Uterine artery embolization. Obstet Gynecol 2004; 103: 403-404 63 213. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zur Uterusarterienembolisation (UAE) zur Myombehandlung – Ergebnisse des 5. Radiologisch-gynäkologischen Expertentreffens. Im Internet: http://www.dggg.de/fileadmin/documents/stellungnahmen/aktuell/2015/213_Stellungnahme_UAE_zur_Myombehandlung1.pdf Stand: 01.12.2016 64 David M, Kröncke T. Uterine fibroid embolisation – Potential impact on fertility and pregnancy outcome. Geburtsh Frauenheilk 2013; 73: 247-255 65 Ruhnke H, Eckey T, Bohlmann MK et al. MR-guided HIFU treatment of symptomatic uterine fibroids using novel feedback-regulated volumetric ablation: effectiveness and clinical practice. Fortschr Röntgenstr 2013; 185: 983-991 66 Toro JR, Travis LB, Wu HJ et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 2006; 119: 2922-2930 67 Hosh M, Antar S, Nazzal A et al. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer 2016; 26: 1098 68 Amant F, Coosemans A, Debiec-Rychter M. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10: 1188-1198 69 Goto A, Takeuchi S, Sugimura K et al. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 2002; 12: 354-361 70 Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83: 414-418 71 Koo YJ, Lee JK, Lee YK et al. Pregnancy outcomes and risk factors for uterine rupture after laparoscopic myomectomy: a single-center experience and literature review. J Minimally Invasive Gynecol 2015; 22: 1022-1028 72 Dubuisson JB, Fauconnier A, Deffarges JV et al. Pregnancy outcome and deliveries following laparoscopic myomectomy. Hum Reprod 2000; 15: 869-873 73 Müller A, Thiel FC, Renner SP et al. Hysterectomy – a comparison of approaches. Dtsch Arztebl Int 2010; 107: 353-359
